TABLE 2

Summary of key studies of immune checkpoint inhibition according to disease type

DiseaseDrugNumber of PatientsResultsStudy TypeReference
HLNivolumab23Confirmed safety and efficacyPhase 1Ansell et al., 2015a
HLPembrolizumab15Confirmed safety and efficacyPhase 1bMoskowitz et al., 2014
HLIpilimumab29Confirmed safety and efficacyPhase 1Bashey et al., 2009
NHLPidilizumab17 total patients; DLBCL = 2; FL = 1Confirmed safety and efficacyPhase 1Berger et al., 2008
FLPidilizumab32Confirmed safety and efficacyPhase 2Westin et al., 2014
NHLPidilizumab66 total patients; DLBCL = 49; indolent B cell NHL = 13; mediastinal B cell lymphoma=4Confirmed safety and efficacyPhase 2Armand et al., 2013
NHLIpilimumab18 total patients; FL = 14; DLBCL = 3; MCL = 1Confirmed safety and efficacyPhase 1Ansell et al., 2009
MMPidilizumab17 total patients; MM = 1Long term stable disease in MM patientPhase 1Berger et al., 2008
MMNivolumab82 total patients; MM = 27No response in the patients with MMPhase 1Lesokhin et al., 2014
MMPembrolizumab34Safety and efficacyPhase 1San Miguel et al., 2015
AML/MDSPidilizumab17 total patients; AML = 8; MDS = 1Minimal response in 1 AML patientPhase 1Berger et al., 2008
  • AML, acute myeloid leukemia; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; HL, Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma.